The histologic type of renal cell carcinoma (RCC) arising in patients with end-stage renal disease (ESRD) may be related to the time on dialysis, according to a study.

Robot-assisted partial nephrectomy (RAPN) is a safe and effective approach for nephron-sparing surgery (NSS) that is capable of providing patients with excellent short-term oncologic outcomes, according to the largest RAPN experience described to date.

Administering sorafenib prior to nephrectomy for renal cell carcinoma (RCC) can reduce the size of the primary tumor with adding to the risk of surgery, according to researchers at the University of North Carolina at Chapel Hill.

Obese individuals with kidney tumors are 48% more likely to develop a clear-cell renal cell carcinoma (RCC) than non-obese individuals, researchers reported in BJU International (2010;105:16-20).

Robot-assisted partial nephrectomy (RAPN) is a safe and effective approach for nephron-sparing surgery (NSS) that is capable of providing patients with excellent short-term oncologic outcomes, according to the largest RAPN experience described to date.

Renal capsular invasion in patients with localized clear-cell renal cell carcinoma (RCC) is associated with an increased risk of cancer recurrence and cancer-related death after surgery, according to researchers at the Catholic University of Korea in Seoul.

The FDA has approved Votrient (pazopanib) for the treatment of advanced renal cell carcinomia (RCC).

Recent therapeutic advances in metastatic renal cell carcinoma (RCC) have included agents targeted against vascular endothelial growth factor (VEGF).

The number and density of positive nodes provide more accurate survival predictions.

Radiofrequency ablation of small renal tumors in otherwise healthy patients preserves renal function.